PL2726470T3 - Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych - Google Patents
Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnychInfo
- Publication number
- PL2726470T3 PL2726470T3 PL12737238T PL12737238T PL2726470T3 PL 2726470 T3 PL2726470 T3 PL 2726470T3 PL 12737238 T PL12737238 T PL 12737238T PL 12737238 T PL12737238 T PL 12737238T PL 2726470 T3 PL2726470 T3 PL 2726470T3
- Authority
- PL
- Poland
- Prior art keywords
- thiadiazol
- treatment
- neurodegenerative diseases
- derivatives useful
- ylpiperazine
- Prior art date
Links
- BLGDMQAEKJZPMD-UHFFFAOYSA-N 5-piperazin-1-yl-1,2,4-thiadiazole Chemical class C1CNCCN1C1=NC=NS1 BLGDMQAEKJZPMD-UHFFFAOYSA-N 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11172324 | 2011-07-01 | ||
| PCT/EP2012/062778 WO2013004642A1 (en) | 2011-07-01 | 2012-06-29 | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
| EP20120737238 EP2726470B1 (en) | 2011-07-01 | 2012-06-29 | 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2726470T3 true PL2726470T3 (pl) | 2015-09-30 |
Family
ID=46545347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12737238T PL2726470T3 (pl) | 2011-07-01 | 2012-06-29 | Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9023852B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2726470B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5972367B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103619825B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012280420B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2837247C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2540956T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2726470T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013004642A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6051218B2 (ja) | 2011-08-17 | 2016-12-27 | リマインド・ナムローゼ・フエンノートシャップＲｅｍｙｎｄ Ｎｖ | アルツハイマー病等のタウオパチーの治療に有用なピペラジンチアジアゾール誘導体 |
| EP3119774A1 (en) * | 2014-03-17 | 2017-01-25 | reMynd NV | Oxadiazole compounds |
| SG11201811023UA (en) * | 2016-06-23 | 2019-01-30 | St Jude Childrens Res Hospital | Small molecule modulators of pantothenate kinases |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| CN110392833A (zh) | 2017-01-06 | 2019-10-29 | 优曼尼蒂治疗公司 | 治疗神经病症的方法 |
| WO2019084157A1 (en) | 2017-10-24 | 2019-05-02 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES THEREOF |
| IL275658B2 (en) | 2017-12-27 | 2024-04-01 | St Jude Childrens Res Hospital Inc | Small molecule modulators of pantothenate kinases |
| AU2018397486B2 (en) | 2017-12-27 | 2025-04-10 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| AU2019238326B2 (en) | 2018-03-23 | 2025-03-06 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| MA54829A (fr) | 2019-01-24 | 2021-12-01 | Yumanity Therapeutics Inc | Composés et leurs utilisations |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| WO2025104092A1 (en) | 2023-11-13 | 2025-05-22 | Remynd N.V. | Modulators of septin 6 for use in the prevention and/or treatment of neurodegenerative disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE268328T1 (de) * | 1999-03-03 | 2004-06-15 | Wyeth Corp | Neue diazol-derivate und ihre verwendung als serotonergische wirkstoffe |
| AU773830B2 (en) * | 1999-04-26 | 2004-06-10 | Neurosearch A/S | Heteroaryl diazacycloalkanes, their preparation and use |
| DE102004032567A1 (de) * | 2004-07-05 | 2006-03-02 | Grünenthal GmbH | Substituierte 1-Propiolyl-piperazine |
| WO2007005510A1 (en) * | 2005-06-30 | 2007-01-11 | Janssen Pharmaceutica N.V. | N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase |
| GB0602335D0 (en) | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| JP2009526059A (ja) * | 2006-02-07 | 2009-07-16 | ワイス | １１−ベータｈｓｄ１阻害剤 |
-
2012
- 2012-06-29 AU AU2012280420A patent/AU2012280420B2/en active Active
- 2012-06-29 CA CA2837247A patent/CA2837247C/en active Active
- 2012-06-29 ES ES12737238.1T patent/ES2540956T3/es active Active
- 2012-06-29 CN CN201280030881.0A patent/CN103619825B/zh active Active
- 2012-06-29 WO PCT/EP2012/062778 patent/WO2013004642A1/en not_active Ceased
- 2012-06-29 US US14/127,779 patent/US9023852B2/en active Active
- 2012-06-29 EP EP20120737238 patent/EP2726470B1/en active Active
- 2012-06-29 JP JP2014517749A patent/JP5972367B2/ja active Active
- 2012-06-29 PL PL12737238T patent/PL2726470T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2726470B1 (en) | 2015-04-29 |
| AU2012280420A1 (en) | 2013-12-12 |
| CA2837247A1 (en) | 2013-01-10 |
| WO2013004642A1 (en) | 2013-01-10 |
| AU2012280420B2 (en) | 2017-01-05 |
| CN103619825B (zh) | 2015-10-14 |
| US9023852B2 (en) | 2015-05-05 |
| US20140128404A1 (en) | 2014-05-08 |
| CN103619825A (zh) | 2014-03-05 |
| EP2726470A1 (en) | 2014-05-07 |
| HK1192726A1 (en) | 2014-08-29 |
| JP5972367B2 (ja) | 2016-08-17 |
| JP2014518240A (ja) | 2014-07-28 |
| CA2837247C (en) | 2020-03-31 |
| ES2540956T3 (es) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2492487B (en) | Cannabinoids for use in the treatment of neurodegenerative diseases or disorders | |
| PL2726470T3 (pl) | Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych | |
| HUE043171T2 (hu) | Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek | |
| AP2014007533A0 (en) | Substituted benzylindazoles for use as BUB1 kinaseinhibitors in the treatment of hyperproliferative diseases | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| EP2991670B8 (en) | Sobetirome in the treatment of myelination diseases | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| AP2014007399A0 (en) | Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament | |
| SI2838539T1 (sl) | Estrogenski derivati za uporabo pri zdravljenju nevroloških motenj | |
| ZA201401678B (en) | Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases | |
| AP2014007804A0 (en) | Compositions and methods for the treatment of hepatic diseases and disorders. | |
| HRP20181950T1 (hr) | Samidorfan (alks 33) u kombinaciji s buprenorfinom za liječenje depresivnih poremećaja | |
| ZA201500547B (en) | Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases | |
| ZA201306613B (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| ZA201308176B (en) | Therapeutic treatment | |
| HK1189818A (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
| HK1193342A (en) | Pharmaceutical combination for use in the treatment of diabetes type 2 | |
| PL395175A1 (pl) | Nowe pochodne dekstrometorfanu i sposób ich wytwarzania |